S&P/ASX Index Rebalance Preview: Review Period Nearly Done; Big Impact Changes
There could be 30 changes for the ASX indices in September with a lot to trade for passive trackers. The adds have outperformed the deletes and...
726 Views
S&P/ASX Index Rebalance Preview: Potential Changes from Now to September
There could be 28 changes for the ASX indices in September with a lot to trade for passive trackers. The adds have outperformed the deletes by a...
772 Views
Clarity Pharmaceuticals (CU6) - O/W: Better Late than Fuzzy
Evaluation of Clarity’s opportunity with their 64Cu-SARbisPSMA PET/CT agent in prostate cancer drives our upgrade in part – recognising that they...
504 Views
Clarity Pharmaceuticals (CU6) - Cash for Copper
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.12/sh (unrisked $7.71/sh). Clarity have recently...
620 Views
Clarity Pharmaceuticals (CU6) - More SECuRE than Ever
Clarity have provided the market with new positive data from both their diagnostic (COBRA) and therapeutic (SECuRE) PSMA prostate cancer (PC)...
486 Views